Guide to HIV Protection Implants and Prevention Options

Understanding HIV protection implants and prevention options can help people learn about the changing landscape of HIV prevention. Modern approaches include oral PrEP, long acting injectable PrEP, vaginal rings, condoms, HIV testing and other prevention strategies. Researchers are also exploring implants and other long acting technologies that could provide convenient protection while reducing the need for frequent medication use.

HIV prevention has developed significantly, giving people more choices based on their health needs, preferences and potential exposure to HIV. Pre exposure prophylaxis, commonly called PrEP, uses antiretroviral medicines to reduce the likelihood of acquiring HIV. Current prevention choices include daily or event based medication in appropriate populations, long acting injections and other approaches.

Understanding HIV Protection Implants and Emerging Approaches

HIV protection implants are being investigated as a possible long acting prevention method. The idea is to place a small device under the skin that could gradually release an HIV prevention medicine over an extended period. This approach could potentially reduce the need for daily pills or frequent medication administration.

However, it is important to distinguish research-stage implants from currently recommended prevention options. WHO has identified subcutaneous implants and other long acting technologies as areas of research, while currently recommended PrEP choices include oral PrEP, long acting injectable cabotegravir and, in relevant settings, the dapivirine vaginal ring.

Key points about emerging implant approaches include:

• Long duration: Researchers are investigating whether implants could deliver prevention medicines continuously.
• Reduced daily dosing: A successful implant could potentially help people who find daily pills difficult to maintain.
• Discreet prevention: An implant could provide a less visible prevention method.
• Ongoing research: Safety, effectiveness, drug release, resistance and appropriate dosing require continued study.
• Not the same as injectable PrEP: Current long acting injections are administered through scheduled injections rather than an implanted device.

These developments show how HIV prevention research is moving toward more convenient and flexible choices.

Exploring Current HIV Prevention Options

People have several established HIV prevention options today. PrEP is specifically designed for people who do not have HIV but may have an increased chance of exposure. According to the CDC, PrEP can substantially reduce the chance of acquiring HIV through sex or injection drug use when used appropriately.

Important prevention approaches include:

• Oral PrEP: PrEP tablets can provide effective protection when taken according to the recommended schedule.
• Long acting injectable PrEP: Cabotegravir is an injectable PrEP option, while lenacapavir is another long acting option administered every six months in settings where it is approved and available. WHO recommends twice-yearly injectable lenacapavir as an additional HIV prevention choice.
• Dapivirine vaginal ring: This is a longer-acting prevention option that has been recommended by WHO for certain women at substantial risk of HIV as part of combination prevention.
• Condoms: Condoms can reduce HIV transmission risk and also provide protection against several other sexually transmitted infections.
• HIV testing: Regular testing can help people understand their status and make appropriate prevention or treatment decisions.
• Combination prevention: Using suitable prevention methods together can provide broader protection depending on individual circumstances.

Prevention choices should be discussed with a qualified healthcare professional, particularly before starting PrEP. HIV testing is important because PrEP is intended for people who do not have HIV, and appropriate testing helps guide safe use.